title: Venous port salvage utilizing low dose tPA.
abstract: This study was performed to evaluate the efficacy of low dose tPA for catheter salvage in cases of fibrin sheath formation in patients with venous access ports. Prospective evaluation was accomplished in patients who had venous ports with catheter malfunction. There were a total of 50 patients and 56 occlusive events. Each patient had a catheter injection documenting a fibrin sheath. Patient population included 45 for chemotherapy and 5 for antibiotics. A low dose tPA regimen was instilled into the port and upon successful return of function, a completion venogram was accomplished. Fifty patients were enrolled in the study with the average time between placement and dysfunction of 99 days. Five patients had a second occlusive event (38.5 days) and one had a third event (27 days). All patients had a venogram confirming a fibrin sheath as the cause of catheter malfunction. The average dose of tPA was 2.29 mg (range 1 mg-4 mg). Success was achieved in 52 of the 56 occlusive events (92.9%). There were no bleeding complications. Catheter occlusion is a common complication of long-term venous access ports. Aggressive therapy with low-dose tPA can salvage function. It provides safe and effective therapy for venous port malfunction secondary to fibrin sheath.
authors.affiliation: Baylor College of Medicine, Department of Radiology, One Baylor Plaza-MS 360, Houston, Texas 77030-3487, USA. cliffw@bcm.tmc.edu
authors.forename: Cliff J
authors.initials: CJ
authors.lastname: Whigham
authors.forename: Jason I
authors.initials: JI
authors.lastname: Lindsey
authors.forename: Chad J
authors.initials: CJ
authors.lastname: Goodman
authors.forename: Richard G
authors.initials: RG
authors.lastname: Fisher
mesh_terms: D002405:Catheterization, Central Venous / Q000009:adverse effects; D002408:Catheters, Indwelling / Q000009:adverse effects; D003974:Diatrizoate Meglumine; D005260:Female; D005337:Fibrin; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D015641:Radiography, Interventional; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*
chemical_list: D005343:Fibrinolytic Agents; D003974:Diatrizoate Meglumine; D005337:Fibrin; D010959:Tissue Plasminogen Activator